4//SEC Filing
Mattes Glenn R. 4
Accession 0001213900-21-016183
CIK 0001733413other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 8:00 PM ET
Size
9.1 KB
Accession
0001213900-21-016183
Insider Transaction Report
Form 4
Mattes Glenn R.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2021-03-15$2.50/sh+50,000$125,000→ 60,000 total - Sale
Common Stock
2021-03-15$17.04/sh−50,000$852,000→ 10,000 total - Exercise/Conversion
Stock Options (Right to Buy)
2021-03-15−50,000→ 944,227 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]10,255 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 25,814 every three months thereafter
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001568678
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 8:00 PM ET
- Size
- 9.1 KB